Tatva chintan pharma Chem Limited has scheduled its quarterly earnings call to discuss the financial performance for the third quarter of fiscal year 2026. The company formally notified stock exchanges about this important investor engagement through a regulatory filing dated January 12, 2026.

Earnings Call Schedule Details

The earnings call is scheduled for Wednesday, January 21, 2026, at 5:00 PM Indian Standard Time. This call will focus on discussing the company's financial results for both the quarter and nine months ended December 31, 2025.

Management Participation

The earnings call will be represented by senior management officials who will provide insights into the company's quarterly performance and address investor queries.

Regulatory Compliance

The company has fulfilled its regulatory obligations by informing both major stock exchanges about the earnings call schedule. The notification was sent to BSE Limited and National Stock Exchange of India Limited under Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Coordination and Contact Information

ICICI Securities is coordinating the earnings call, with multiple contact persons available for clarifications and registration assistance. The coordination team includes:

• Mr. Jaideep Goswami, Head of Equities
• Mr. Sanjesh Jain and Mr. Mohit Mishra as primary coordinators
• Mr. Rushad Kapadia, Ms. Seema Sehgal, and Ms. Minali Ginwala for clarifications

The company has also made this information available on its official website at www.tatvachintan.com for broader accessibility to stakeholders and investors interested in the company's quarterly performance discussion.

Tatva Chintan Pharma Chem Ltd. has reported a remarkable turnaround in its financial performance for the second quarter, showcasing significant improvements across key metrics.

Financial Highlights

Key Takeaways

Profitability Turnaround

Tatva Chintan Pharma Chem has successfully reversed its financial trajectory, reporting a net profit of ₹99.20 crore in Q2, compared to a loss of ₹6.64 crore in the same quarter of the previous year.

Strong Revenue Growth

The company's revenue witnessed a substantial increase of 48.50%, rising to ₹124.00 crore from ₹83.50 crore year-over-year.

Improved Operational Efficiency

EBITDA saw a significant boost, climbing to ₹22.20 crore from ₹5.60 crore in the corresponding quarter last year, representing a 296.43% increase.

Enhanced Profitability

The EBITDA margin expanded impressively to 17.90% from 6.71%, indicating a substantial improvement in the company's operational efficiency and cost management.

This turnaround in Tatva Chintan Pharma Chem's financial performance demonstrates the company's ability to navigate challenges and capitalize on market opportunities. The significant improvements across revenue, profitability, and operational efficiency suggest a positive outlook for the company's future growth prospects in the pharmaceutical sector.